Skip to main content
Delfa

← Trials/Trial dossier/NCT06586606

CompletedPhase 1

A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)

A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single Dose PK of MK-1708 in Healthy Participants

Asset

MK-1708

Listed sites

1

Recruiting sites

-

Enrollment

12

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age 18-50

Primary endpoints

•AUC from Time 0 to Infinity (AUC0-Inf) of MK-1708•Number of Participants Who Experience an Adverse Event (AE)•Number of Participants Who Discontinue Study Due to an AE

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID1708-003
Secondary IDMK-1708-003MSD
NCT IDNCT06586606

Timeline

Milestones

Study first posted2024-09-19actual
Study start2024-10-03actual
Primary completion2024-12-10actual
Study completion2024-12-10actual
Last update posted2024-12-18actual

Assets

Drug assets

MK-1708

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

•Is in good health before randomization
•Has a body mass index (BMI) ≥18.5 and ≤32 kg/m^2, inclusive

Exclusion criteria

The key exclusion criteria include but are not limited to the following:

•Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
•Has a history of cancer

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
5
Other (unclassified)
5

Safety / tolerability / PK

5 endpoints
Primary/protocol endpoint

Number of Participants Who Experience an Adverse Event (AE)

Time frame:Up to approximately 11 weeks

event count, event

Secondary/protocol endpoint

Maximum Plasma Concentration (Cmax) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

concentration, descriptive

Secondary/protocol endpoint

Time to Maximum Plasma Concentration (Tmax) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

time to event, event

Secondary/protocol endpoint

Plasma Concentration at 24 Hours (C24) of MK-1708

Time frame:Predose and at designated timepoints up to 24 hours postdose

concentration, descriptive

Secondary/protocol endpoint

Apparent Terminal Half-life (t1/2) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

concentration, descriptive

Other (unclassified)

5 endpoints
Primary/protocol endpoint/low confidence

Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

concentration, descriptive

Primary/protocol endpoint/low confidence

Number of Participants Who Discontinue Study Due to an AE

Time frame:Up to approximately 11 weeks

event count, event

Secondary/protocol endpoint/low confidence

Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration (AUC0-Last) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Apparent Clearance (CL/F) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

descriptive

Secondary/protocol endpoint/low confidence

Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-1708

Time frame:Predose and at designated timepoints up to approximately 2 weeks postdose

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.